Compare LOB & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | STOK |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2015 | 2019 |
| Metric | LOB | STOK |
|---|---|---|
| Price | $39.08 | $29.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $40.00 | $34.50 |
| AVG Volume (30 Days) | 337.0K | ★ 712.6K |
| Earning Date | 01-21-2026 | 03-17-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ 31.95 | N/A |
| EPS | ★ 2.23 | 0.68 |
| Revenue | ★ $480,778,000.00 | $205,632,000.00 |
| Revenue This Year | $34.85 | $430.24 |
| Revenue Next Year | $14.31 | N/A |
| P/E Ratio | ★ $17.65 | $43.03 |
| Revenue Growth | 19.32 | ★ 1128.17 |
| 52 Week Low | $22.68 | $5.35 |
| 52 Week High | $42.89 | $38.69 |
| Indicator | LOB | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 44.58 |
| Support Level | $38.52 | $28.75 |
| Resistance Level | $42.89 | $30.96 |
| Average True Range (ATR) | 1.49 | 2.05 |
| MACD | 0.22 | -0.32 |
| Stochastic Oscillator | 45.73 | 35.86 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.